Glycine receptor subunit alpha-1 (GLRA1) and Glycine receptor subunit alpha-3 (GLRA3) (GLRA1/GLRA3)

The Glycine receptor subunit alpha-1 (GLRA1) and alpha-3 (GLRA3) are essential components of the glycine-gated chloride channel, a member of the Cys-loop family of ligand-gated ion channels [UniProt P23415, P24347]. GLRA1 is the most abundant subunit in the adult spinal cord and brainstem, where it mediates fast inhibitory synaptic transmission crucial for motor coordination [PubMed: 25101672]. Mutations in the GLRA1 gene are the leading cause of hyperekplexia, a disorder characterized by an exaggerated startle response and muscle stiffness [NIH: GeneReviews]. GLRA3 is specifically localized in the superficial layers of the spinal dorsal horn and is a key player in nociceptive processing [PubMed: 15141213]. During inflammation, prostaglandin E2 (PGE2) activates protein kinase A, which phosphorylates and inhibits GLRA3, leading to reduced synaptic inhibition and increased pain sensitivity [PubMed: 15141213]. Therapeutic strategies focus on developing positive allosteric modulators (PAMs) for GLRA3 to restore inhibition and alleviate chronic pain, while GLRA1 remains a target for treating spasticity [PubMed: 33564115]. Challenges in drug discovery include achieving selectivity between GlyR subunits and avoiding cross-reactivity with GABA-A receptors [PubMed: 21490318]. These receptors are also modulated by various substances including ethanol, general anesthetics, and cannabinoids, which contribute to their pharmacological profile [PubMed: 25101672].

Other names

GLRA1GLRA3GlyR alpha 1GlyR alpha 3Glycine receptor alpha 1Glycine receptor alpha 3Glycine receptor subunit alpha-1Glycine receptor subunit alpha-3

Drugs targeting these subunits typically act as agonists or positive allosteric modulators to enhance inhibitory chloride conductance, thereby reducing neuronal excitability [PubMed: 25101672]. Conversely, antagonists like strychnine block the channel, leading to over-excitation and muscle spasms [PubChem].